STOCK TITAN
  1. Home
  2. News
  3. AXLA

Axcella to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that management will participate in the following upcoming investor conferences:

  • SVB Leerink 10th Annual Global Healthcare Conference: The company’s fireside chat will be webcast on February 26, 2021 at 9:20 a.m. ET.
  • H.C. Wainwright Global Life Sciences Conference: The company’s presentation will be webcast on March 9, 2021 at 7:00 a.m. ET.
  • 33rd Annual Roth Conference: The company’s fireside chat will be webcast on March 15, 2021 at 9:00 a.m. ET.

The audio webcasts will be accessible on the “Investors & News” section of the company’s website, www.axcellahealth.com, for 90 days following the presentations.

Internet Posting of Information

Axcella uses its website, www.axcellahealth.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company’s website in the “Investors and News” section. Accordingly, investors should monitor this portion of the company’s website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

About Axcella

Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. For more information, please visit www.axcellahealth.com.

Stock AXLA logo
Axcella Health Inc.

NASDAQ:AXLA

AXLA Rankings

N/A Ranked by Market Cap
#5313 Ranked by Stock Gains
N/A Ranked by Dividends

AXLA Latest News

Sep 14, 2023
Axcella Announces Reverse Stock Split Effective September 19, 2023
Aug 29, 2023
Axcella Granted Patent for Long COVID Fatigue Treatment
Aug 3, 2023
Axcella Reports Second Quarter Financial Results and Provides Business Update
May 4, 2023
Axcella Reports First Quarter Financial Results and Provides Business Update
Apr 17, 2023
Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023

AXLA Stock Data

1.18M
1.07M
15.8%
55.8%
2.65%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Cambridge

About AXLA

axcella has pioneered a new therapeutic class – defined amino acid compositions (daacs™). our daac therapeutics leverage the essential signaling function of amino acids to restore health across a network of dysregulated pathways, and provide safer solutions for patients with complex disease. with our axcellerator™ platform, we are transforming traditional drug discovery and development by generating patient data in less than a year from indication selection. this platform has delivered a rich pipeline including clinical programs in liver, metabolic, cns and orphan diseases.